Showing Metabocard for 5-phospho-beta-D-ribosylamine (BASm0003626)

Common Name5-phospho-beta-d-ribosylamine
Description5-Phosphoribosylamine is a substrate for Amidophosphoribosyltransferase and Trifunctional purine biosynthetic protein adenosine-3.
Structure
Molecular FormulaC5H12NO7P
Average Mass229.12500
Monoisotopic Mass229.03514
IUPAC Name{[(2R,3S,4R,5R)-5-amino-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
Traditional Name[(2r,3s,4r,5r)-5-amino-3,4-dihydroxyoxolan-2-yl]methoxyphosphonic acid
CAS Registry Number6062-06-02
SMILES[NH3+][C@@H]1O[C@H](COP(=O)([O-])[O-])[C@@H](O)[C@H]1O
InChI IdentifierInChI=1S/C5H12NO7P/c6-5-4(8)3(7)2(13-5)1-12-14(9,10)11/h2-5,7-8H,1,6H2,(H2,9,10,11)/t2-,3-,4-,5-/m1/s1
InChI KeySKCBPEVYGOQGJN-TXICZTDVSA-N
CHEBI IDCHEBI:58681
HMDB IDHMDB0001128
Pathways
NameSMPDB/PathBank
Purine metabolism
Glutamate Metabolism
2-Hydroxyglutric Aciduria (D And L Form)
Adenosine Deaminase Deficiency
Adenylosuccinate Lyase Deficiency
AICA-Ribosiduria
Molybdenum Cofactor Deficiency
Purine Nucleoside Phosphorylase Deficiency
Xanthine Dehydrogenase Deficiency (Xanthinuria)
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency
Hyperinsulinism-Hyperammonemia Syndrome
Lesch-Nyhan Syndrome (LNS)
Gout or Kelley-Seegmiller Syndrome
Homocarnosinosis
Azathioprine Action Pathway
Mercaptopurine Action Pathway
Thioguanine Action Pathway
Xanthinuria type I
Xanthinuria type II
Adenine phosphoribosyltransferase deficiency (APRT)
Mitochondrial DNA depletion syndrome
Myoadenylate deaminase deficiency
Succinic semialdehyde dehydrogenase deficiency
StateSolid
Water Solubility3.82e+01 g/l
logP-2.39
logS-0.78
pKa (Strongest Acidic)1.23
pKa (Strongest Basic)8.00
Hydrogen Acceptor Count7
Hydrogen Donor Count5
Polar Surface Area142.47 Ų
Rotatable Bond Count3
Physiological Charge-1
Formal Charge0
Refractivity42.49 m³·mol⁻¹
Polarizability18.66

We require the use of cookies for essential features like storing your previously submitted BASys2 queries. Rejecting the usage of cookies will result in certain features being disabled. By clicking ACCEPT or continuing to use the website you are agreeing to our use of cookies.

ACCEPT